Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project.

ABSTRACT:

Purpose

Although treatment for early breast cancer improved prognosis greatly, it can have significant long-term consequences, which must be considered during treatment decision.

Methods

453 patients with neoadjuvant or adjuvant treatment intention were recruited into the MaTox project within the prospective, multicentre, population-based German TMK cohort study (Tumour Registry Breast Cancer) between 2008 and 2009. Patient-reported outcomes (PROs) on 26 treatment-related symptoms were assessed via a specifically designed questionnaire at 4 weeks, 6 months, 18 months and 3 years after start of systemic treatment.

Results

The results show that alterations in smell, taste and appetite were clearly improved 3 years after treatment. In contrast, post-surgical symptoms, re

SUBMITTER: Hurtz HJ 

PROVIDER: S-EPMC5602000 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature